---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-004481"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2023-02-13T23:59:59+00:00"
generated_at: "2026-06-19T15:59:21.534173+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Processa Pharmaceuticals raises $6.25M in registered direct offering at $0.80/share

## Summary
- Sold 7,812,544 shares at $0.80/share; gross proceeds $6.25M, net ~$5.7M after fees.
- Closing expected Feb 14, 2023; Spartan Capital acted as sole placement agent.
- Proceeds to fund clinical trials, R&D, working capital, and general corporate purposes.
- Issuer subject to 90-day lockup until stock exceeds $2.00 for 10 consecutive trading days.

## SEC filing metadata
- accession: 0001493152-23-004481
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2023-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000149315223004481/0001493152-23-004481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000149315223004481/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-004481
- JSON: https://secwatch.observer/filing/0001493152-23-004481.json
- Plain text: https://secwatch.observer/filing/0001493152-23-004481.txt

## Key facts
- Material Agreements
  Processa Pharmaceuticals, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $6.25 million (effective 2023-02-09).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: approximately $6.25 million
  - Effective: 2023-02-09
  source text: On February 9, 2023, Processa Pharmaceuticals, Inc. (the “Company”) and certain accredited investors (the “Investors”) entered into a securities purchase agreement (the “Purchase Agreement”) relating to the issuance and sale of shares of common stock pursuant to a registered direct offering (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533743/000149315223004481/0001493152-23-004481-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.